Company Description
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.
The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules.
Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist.
Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations.
The company was founded in 2024 and is based in Waltham, Massachusetts.
| Country | United States |
| Founded | 2024 |
| IPO Date | Apr 17, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 145 |
| CEO | Ronald Renaud |
Contact Details
Address: 180 Third Avenue, 4th Floor Waltham, Massachusetts 02451 United States | |
| Phone | 781 317 0290 |
| Website | kailera.com |
Stock Details
| Ticker Symbol | KLRA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 2096997 |
| CUSIP Number | 482931102 |
| ISIN Number | US4829311020 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ronald C. Renaud, Jr. | President, Chief Executive Officer and Director |
| Scott Akamine | Chief Legal Officer and Secretary |
| Paul Burgess | Chief Operating Officer and Chief Business Officer |
| Paula Cloghessy | Chief People Officer |
| Jamie Coleman | Chief Commercial Officer |
| Douglas Pagán | Chief Financial Officer |
| Scott Wasserman, M.D. | Chief Medical Officer |
| John F. Milligan, Ph.D. | Chairman |
| Frank Clyburn, Jr. | Director |
| Michael Gladstone | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2026 | SCHEDULE 13D | Filing |
| Apr 23, 2026 | SCHEDULE 13D | Filing |
| Apr 20, 2026 | 8-K | Current Report |
| Apr 17, 2026 | 424B4 | Prospectus |
| Apr 17, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 16, 2026 | EFFECT | Notice of Effectiveness |
| Apr 16, 2026 | S-1MEF | Registration adding securities to prior Form S-1 registration |
| Apr 15, 2026 | CERT | Certification by an exchange approving securities for listing |
| Apr 14, 2026 | 8-A12B | Registration of securities |
| Apr 13, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |